The National Institute of Neurological Disorders and Stroke (NINDS) invites small business innovative research (SBIR) applications for NINDS cooperative small business awards in translational research.*
Translational research is the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.
Phase I award feasibility projects are intended to discover potential targets for therapeutic intervention; identify candidate therapeutics; develop assays, animal models, devices, or technologies for screening or developing therapeutics; or obtain preliminary data on the efficacy of candidate therapeutics. Such projects, if successful, should lead directly to a therapy development project for a particular neurological disorder.
Goals of phase 1 projects include, but are not limited to: identification of targets for therapeutic intervention; development of assays that permit the preliminary screening of candidate therapeutics; development of animal models that permit further evaluation of candidate therapeutics and/or toxicology studies; development of tools and technologies that can be directly used for therapy development; preliminary identification of candidate therapeutics that can be evaluated through further preclinical testing; and testing of therapeutics for efficacy in cell-based or animal models of a neurological disorder.
Phase II awards are cooperative agreements that support translational research projects focused on a single problem or approach in therapy development for a neurological disorder. The research focuses on a single neurological disorder or a group of closely related neurological disorders. Each research project should include a translational research focus and specific milestones of progress toward disease intervention.
For more information, potential applicants should contact Dr. Thomas Miller, Program Director, Technology Development Group,
NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2139, Bethesda, MD 20892; telephone:
301-496-1779; fax: 301-402-1501; e-mail: firstname.lastname@example.org.
*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PAR-06-005.html.